The educational activity and outcomes measurement was funded through independent educational grants from an unrestricted educational grant from Celgene Corporation (Summit, NJ), Onyx Pharmaceuticals, Inc. (South San Francisco, CA), and Novartis Oncology (St. Louis, MO). Onyx Pharmaceuticals, Inc. provided partial funding for the e-learning module. Dr. Prabhat is supported by the National Cancer Institute under Award Number R01CA191205. Dr. Keating is supported by the National Cancer Institute under Award Number K08CA172543. Dr. Swerdlow is supported by the National Cancer Institute under Award Number T32CA095674. Drs. K. D. Drucker and S. O. Petrylak are employed by Celgene Limited. Drs. W. W. J. Palumbo, A. Bringhen, H. Ludwig, F. J. V. Carrasco, G. Cavo, O. L. Driver, E. Dimopoulos, R. D'Hollander, G. M. A. van Rhee, and C. Beksac are employed by and own stock in Celgene Corporation. Dr. P. Sonneveld is employed by and owns stock in Novartis International. Dr. D. Raje is employed by and owns stock in Celgene Corporation. Dr. A. Palumbo is employed by and owns stock in Celgene Corporation and Berkeley Pharmaceuticals, Inc. Dr. M. R. Desikan is employed by and owns stock in Celgene Corporation and Berkeley Pharmaceuticals, Inc. Dr. D. Muratore is employed by and owns stock in Celgene Corporation and Berkeley Pharmaceuticals, Inc.